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Abstract
Propafenone, a Class IC antiarrhythmic drug, is an orally active sodium channel-blocking agent. 
It is effective in supraventricular tachyarrhythmias and is particularly useful in converting atrial 
fibrillation to sinus rhythm. In therapeutic doses, it may cause non-cardiac and cardiac toxicity, 
including  proarrhythmia.
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Case Report
A 69 year-old female with hypertension and paroxysmal atrial fibrillation presented with 
palpitations and dyspnea. Her current medications included enalapril, atenolol and amiodarone. 
Physical examination showed heart rate 140 bpm and irregular. Blood pressure was 140/90 mm 
Hg. There was no evidence of heart failure. She was initially treated with verapamil 5 mg (IV) 
for rate control and propafenone 600 mg (orally) for pharmacological cardioversion. Being 
admitted, the patient reported rapid palpitations, dizziness and increased dyspnea. A 12-lead 
electrocardiogram (ECG) showed self-limited wide QRS complex tachycardia (Figure 1A) at a 
heart rate of 150 bpm with right bundle branch block (RBBB) morphology in lead V1 and left 
axis deviation. Ventricular tachycardia was suspected. To elucidate the mechanism of the wide 
QRS complex tachycardia, the patient was referred to our institution for an invasive EP study. 
However, before the study and after propafenone discontinuation, another 12-lead ECG showed 
typical right sided isthmus dependent atrial flutter (AFL) with variable AV conduction (Figure 
1B). This rose the suspicion of a proarrhythmic tachycardia induced by propafenone. Typical 
flutter was confirmed and RF ablation was successfully performed. (Figure 2A-B).
Discussion
Propafenone is a class IC antiarrhythmic drug that is commonly used for atrial fibrillation 
treatment [1]. However, as shown in this case, its use is not complication free. These agents act by 
slowing sodium influx into myocytes through voltage gated sodium channels, and are referred to 
us as sodium-channel blockers. They differ in their affinity and duration of binding to the sodium 
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channel, in their effects on potassium and calcium channels, and in other effects such as 
anticholinergic properties. Class IC agents are the most potent sodium-channel blockers but do not 
affect   potassium   channels;   therefore   these   agents   cause   QRS   prolongation   without   QT 
prolongation [2].
Figure 1: 12-lead electrocardiogram A: Wide QRS complex tachycardia. Heart rate at 150 bpm, with right bundle 
branch block morphology, left axis deviation and visible atrial activity in V1 V2 (arrow). B: Typical atrial flutter 
with   variable   AV   conduction.                                                                              
Figure 2: A: Radiofrecuency ablation. Termination of atrial flutter during RF application. Normal sinus rhythm is 
restored.   B: Normal sinus rhythm after RF ablation                                                                                         .
Metabolism of propafenone is mediated by the cytochrome P-450 (CYP) isoenzyme system, 
including CYP2D6 (major metabolic pathway), CYP1A2 and CYP3A4. Patients should be 
monitored and dosage of propafenone should be reduced accordingly when the drug is used 
concurrently with other inhibitors of CYP2D6 (e.g.: quinidine) and CYP1A2 (e.g.: amiodarone) 
because plasma concentrations may increase. In therapeutic doses, propafenone may cause non-
cardiac and cardiac toxicity including: agranulocytosis, reactive airway disease, hemolysis, drug 
fever, ataxia, hypotension, prolonged QRS duration, ventricular arrhythmias, depressed mental 
status, seizures and sudden death. The overall incidence of proarrhythmia with propafenone is 
unknown. It was reported as high as 5-10% [3]. Class 1C antiarrhytmic drugs significantly slow 
conduction velocity of the atrial tissue with moderate effects on the prolongation of refractory 
periods, including the atrioventricular node. Consequently, slowing the AFL cycle length may 
lead to 1:1 atrioventricular conduction, and widening of the QRS complex [4].                     
The ventricular response during AFL is determined by the refractory period of the AV node, the 
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degree of concealed conduction within the node, and the status of the autonomic tone. The 
association   of   1:1   AFL   with   high   catecholamine   levels   has   been   previously   described. 
Sympathetic tone might play an important role in the occurrence of 1:1 AFL [5]. Kawabata et al 
[5] showed that 1:1 AFL can occur during physical activity linking to a life-threatening 
haemodynamic status (syncope, presyncope and shock). In the differential diagnosis, one must 
exclude   ventricular   tachycardia   and   extreme   aberrant   conduction,   mimicking   ventricular 
tachycardia. This exercise is not always easy because of the QRS widening, high ventricular rate 
and   hemodynamic   intolerance.   Vagal   maneuvers   can   sometimes   increase   the   degree   of 
atrioventricular block unmasking atrial flutter and usually, all the conventional criteria for 
ventricular tachycardia are not present.                                                                                   
Propafenone can produce sustained monomorphic ventricular tachycardia, which is characterized 
by a marked increase in QRS duration and not associated with QT interval prolongation. Its heart 
rate is relatively slow but tends to be incessant. The mechanism of this proarrhythmic effect is 
likely to be due to a delay of conduction in the His-Purkinje system. This effect may encourage 
reentry by allowing extra time for refractory tissue to recover, thus allowing it to be reexcited [6].
Conclusion
Propafenone is a useful drug for the treatment o atrial fibrillation. It has proarrhythmic effects, 
such as 1:1 conducted atrial flutter and ventricular tachycardia. Rapid recognition of these 
complications allows discontinuing the medication and resolution of the proarrhythmia.         
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